We are live on ! Find out more
NVO

Novo Nordisk

432 hedge funds and large institutions have $6.39B invested in Novo Nordisk in 2013 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 182 increasing their positions, 121 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 182 | Existing positions reduced: 121

45% more funds holding in top 10

Funds holding in top 10: 1116 (+5)

29% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 41

18% more call options, than puts

Call options by funds: $39M | Put options by funds: $33M

2% more funds holding

Funds holding: 425432 (+7)

1% more capital invested

Capital invested by funds: $6.3B → $6.39B (+$85M)

1.97% less ownership

Funds ownership: 84.17%82.2% (-2%)

Holders
432
Holders Change
+7
Holders Change %
+1.65%
% of All Funds
12.49%
Holding in Top 10
16
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+45.45%
% of All Funds
0.46%
New
53
Increased
182
Reduced
121
Closed
41
Calls
$39M
Puts
$33M
Net Calls
+$6.01M
Net Calls Change
+$703K

NVO Hedge Fund Activity: Q4 2013 in Review

432 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2013, worth a combined $6.39B — up 1.3% from $6.3B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new NVO positions and 41 closed out — a net gain of 12 holders — while 182 added to existing stakes and 121 trimmed.

The largest buyer was WCM Investment Management, adding an estimated $143M. The largest seller was Ameriprise, cutting an estimated $205M.

  • 432 institutional investors held Novo Nordisk (NVO) as of Q4 2013, up from 425 in Q3 2013.
  • Funds reported $6.39B of Novo Nordisk stock for Q4 2013, up 1.3% quarter-over-quarter.
  • 53 funds opened new Novo Nordisk positions in Q4 2013 and 41 closed out, a net change of +12 holders.
  • The largest Novo Nordisk buyer in Q4 2013 was WCM Investment Management, an estimated $143M added.
  • The largest Novo Nordisk seller in Q4 2013 was Ameriprise, an estimated $205M sold.

Based on aggregated 13F filings for Q4 2013.